Vulcan Value Partners LLC Has $99.16 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Key Points

• Vulcan Value Partners LLC significantly increased its stake in Medpace Holdings, purchasing 224,578 shares, resulting in a total of 325,916 shares, which makes up 1.9% of its investment portfolio.
• Medpace's stock recently had a target price adjustment by several brokerages, with Barclays boosting its target from $300 to $450, while TD Cowen raised theirs from $283 to $366.
• CEO August J. Troendle sold 48,487 shares for approximately $21.9 million, which reduced his ownership in the company by 4.8% amid a broader trend of insider selling totaling $51 million in the last quarter.

Vulcan Value Partners LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 221.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 325,916 shares of the company's stock after purchasing an additional 224,578 shares during the period. Medpace accounts for approximately 1.9% of Vulcan Value Partners LLC's investment portfolio, making the stock its 17th biggest holding. Vulcan Value Partners LLC owned approximately 1.13% of Medpace worth $99,159,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Whittier Trust Co. increased its stake in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of Medpace by 150.0% during the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after acquiring an additional 105 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Medpace during the 1st quarter worth $60,000. Assetmark Inc. grew its position in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the last quarter. Finally, Nemes Rush Group LLC bought a new stake in Medpace during the 4th quarter worth $86,000. Institutional investors own 77.98% of the company's stock.

Insider Buying and Selling

In other news, President Jesse J. Geiger sold 41,801 shares of the business's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president directly owned 36,503 shares of the company's stock, valued at $16,539,874.33. The trade was a 53.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 112,788 shares of company stock worth $51,018,354 over the last three months. Insiders own 20.30% of the company's stock.

Medpace Stock Up 0.3%

Shares of NASDAQ MEDP traded up $1.48 during trading on Tuesday, reaching $433.91. The company had a trading volume of 207,943 shares, compared to its average volume of 461,131. The stock has a market cap of $12.19 billion, a P/E ratio of 32.26, a PEG ratio of 2.66 and a beta of 1.42. The company's fifty day moving average price is $336.26 and its 200-day moving average price is $324.63. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%. The firm's revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MEDP shares. Robert W. Baird boosted their price objective on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their price objective on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. William Blair restated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Barclays boosted their price objective on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, Mizuho boosted their price objective on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $406.60.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.